Prognostic significance of cathepsins B and L in primary human breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1013-1021

  Foekens, John A ^a   Kos, Janko ^a   Peters, Harry A ^a   Kraovec, Marta ^a   Look, Maxime P ^a   Cimerman, Nina ^a   Meijer van Gelder, Marion E ^a   Henzen Logmans, Sonja C ^a   Van Putten, Wim L J ^a   Klijn, Jan G M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEINASE; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031887693     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1013     Document Type: Article

References (50)

1. Liotta LA, Thorgeirsson UP, Garcia S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1:277-297, 1982
2. Danø K, Andreasen PA, Grøndahl-Hansen J, et al: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266, 1985
3. Schmitt M, Jänicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 6:3-26, 1992 (suppl 4)
4. Mignatti P, Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195, 1993
5. Andreasen PA, Kjøller L, Christensen L, et al: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72: 1-22, 1997
6. Duffy MJ, O'Grady P, Devaney D, et al: Urokinase plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report. Cancer 62:531-533, 1988
7. Thorpe SM, Rochefort H, Garcia M, et al: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary breast cancer. Cancer Res 49:6008-6014, 1989
8. Spyratos F, Maudelonde T, Brouillet J-P, et al: Cathepsin D: Independent prognostic factor for metastasis of breast cancer. Lancet 2:1115-1118, 1989
9. Rochefort H, Capony F, Garcia M: Cathepsin D: A protease involved in breast cancer metastasis. Cancer Metastasis Rev 9:321-331, 1990
10. Jänicke F, Schmitt M, Hafter R, et al: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69-78, 1990
11. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2:613-618, 1996
12. Westley BR, May FEB: Cathepsin D and breast cancer. Eur J Cancer 32A:15-14, 1996
13. Foekens JA, van Putten WLJ, Portengen H, et al: Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 11:899-908, 1993
14. Foekens JA, Berns EMJJ, Look MP, et al: Prognostic factors in node-negative breast cancer, in Pasqualini JR, Katzenellebogen BS (eds): Hormone-Dependent Cancer. New York, NY, Dekker, 1996, pp 217-253
15. Schmitt M, Harbeck N, Thomssen C, et al: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thromb Hemostas 78:285-296, 2997
16. Mason RW, Johnson DA, Barrett AJ, et al: Elastinolytic activity of human cathepsin L. Biochem J 233:925-927, 1986
17. Chauhan SC, Goldstein LJ, Gottesman MM: Expression of cathepsin L in human tumors. Cancer Res 51:1478-1481, 1991
18. Sloane BF: Cathepsin B and cystatins: Evidence for a role in cancer progression. Semin Cancer Biol 1:137-152, 1990
19. Berquin IM, Sloane BF: Cathepsin B expression in human tumors. Adv Exp Med Biol 389:281-294, 1996
20. Kobayashi H, Schmitt M, Goretzki L, et al: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266:5147-5152, 1991
21. Goretzki L, Schmitt M, Mann K, et al: Effective activation of the proenzyme form of the urokinase-type plasminogen activator (uPA) by the cysteine protease cathepsin L. FEBS Lett 297:112-118, 1992
22. Dalet-Fumeron V, Guinec N, Pagano M: High-performance liquid chromatography method for the simultaneous purification of cathepsins B, H and L from human liver. FEBS Lett 332:251-254, 1993
23. Kane SE, Gottesman MM: The role of cathepsin L in malignant transformation. Semin Cancer Biol i:127-136, 1990
24. Sloane BF, Moin K, Lah TT: Lysosomal enzymes and their endogenous inhibitors in neoplasia, in Pretlow TG, Pretlow TH (eds): Biochemical and Molecular Aspects of Selected Cancers, vol 2. New York, NY, Academic Press, 1994, pp 411-466
25. Mort JS, Recklies AD: Interrelationship of active and latent secreted human cathepsin B precursors. Biochem J 233:57-63, 1986
26. Krepala E, Bartek J, Skalkova D, et al: Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells. J Cell Science 87:145-154, 1987
27. Lah TT, Kokalj-Kunovar M, Strukelj B, et al: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 50:36-44, 1992
28. Gabrijelcic D, Svetic B, Spaic D, et al: Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 30:69-74, 1992
29. Lah TT, Calaf G, Kalman E, et al: Cathepsins D, B and L in breast carcinoma and in transformed human breast epithelial cells (HBEC). Biol Chem Hoppe Seyler 376:357-363, 1995
30. Thomssen C, Schmitt M, Goretzki L, et al: Prognostic value of the cysteine proteases cathepsin B and L in human breast cancer. Clin Cancer Res 1:741-746, 1995
31. Barrett AJ, Rawling ND, Davies ME, et al: Cysteine proteinase inhibitors of cystatins family, in Barrett A, Salvesen G (eds): Proteinase Inhibitors. Amsterdam, the Netherlands, Elsevier, 1986, pp 514-549
32. Turk V, Jerala R, Lenarcic B, et al: Structural and functional aspects of human cathepsins B, H and L and their endogenous protein inhibitors, stefins, in Katunuma N, Kominami E (eds): Intracellular Proteolysis: Mechanism and Regulation. Tokyo, Japan, Japanese Scientific Society Press, 1989, pp 27-34
33. Foekens JA, Schmitt M, van Putten WLJ, et al: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992
34. Van Putten WLJ, Klijn JGM, Meijer-van Gelder ME, et al: Multiparameter analysis of prognostic factors in breast cancer, in Calvo F, Crepin M, Magdelenat H (eds): Breast Cancer Advances in Biology and Therapeutics. Montrouge, France, John Libbey Eurotext, 1996, pp 209-215
35. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16:1513-1515, 1980
36. Foekens JA, Portengen H, van Putten WLJ, et al: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassay in human breast tumor cytosols. Cancer Res 49:5823-5828, 1989
37. Kos J, Smid A, Krasovec M, et al: Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 376:401-405, 1995
38. Dolinar M, Barlic-Magajna D, Turk V: Expression of full-length human procathepsin L cDNA in Escherichia coli and refolding of the expression product. Biol Chem Hoppe Seyler 376:385-388, 1995
39. Barlow RE, Bartelomew DJ, Bremmer JM, et al: Statistical interference under order restrictions. London, England, Wiley, 1972
40. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
41. Gray RJ: Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942-951, 1992
42. Schmitt M, Thomssen C, Ulm K, et al: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer, 76:306-311, 1997
43. Gore SMC, Pocock SJ, Kerr GR: Regression models and non-proportional hazards in the analysis of breast cancer survival. Appl Stat 33:176-195, 1984
44. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
45. Osborne CK: Prognostic factors for breast cancer: Have they met their promise? J Clin Oncol 10:679-682, 1992
46. Gasparini G, Gozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in axillary node-negative breast cancer patients. J Natl Cancer Inst 12:1006-1014, 1992
47. Budihna M, Skrk J, Zakotnik B, et al: Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur J Cancer 31A:661-664, 1995
48. Thomssen C, Oppelt P, Jänicke F, et al: Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res (in press)
49. Lah TT, Buck MR, Honn KV, et al: Degradation of laminin by human tumor cathepsin B. Clin Exp Metastasis 7:461-468, 1989
50. Buck MR, Karustis DG, Day NA, et al: Degradation of extracellular matrix proteins by human cathepsin B from normal and tumor tissues. Biochem J 282:2273-2278, 1992